AIM: The adrenolytic agent mitotane is widely used in the treatment of adrenocortical cancer; however, its mechanism of action is poorly elucidated. We have studied mitotane-induced mRNA expression changes in the NCI-H295R adrenocortical cancer cell line. MATERIALS & METHODS: Cell viability and hormone assays were used to select the optimal mitotane concentration effectively inhibiting hormone secretion without affecting cell viability. RNA isolated from cultures treated for 48 and 72 h was subjected to Agilent 4×44K microarray platforms. Microarray results were validated by quantitative reverse-transcription PCR. RESULTS: Altogether, 117 significantly differentially expressed genes were detected at 48 h and 72 h (p < 0.05) in mitotane-treated samples relative to controls. Three significantly underexpressed genes involved in steroid hormone biosynthesis (HSD3B1, HSD3B2 and CYP21A2) and four significantly overexpressed genes (GDF15, ALDH1L2, TRIB3 and SERPINE2) have been validated. CONCLUSION: Gene-expression changes might be involved in the adrenal action of mitotane and in the inhibition of hormone secretion.
AIM: The adrenolytic agent mitotane is widely used in the treatment of adrenocortical cancer; however, its mechanism of action is poorly elucidated. We have studied mitotane-induced mRNA expression changes in the NCI-H295R adrenocortical cancer cell line. MATERIALS & METHODS: Cell viability and hormone assays were used to select the optimal mitotane concentration effectively inhibiting hormone secretion without affecting cell viability. RNA isolated from cultures treated for 48 and 72 h was subjected to Agilent 4×44K microarray platforms. Microarray results were validated by quantitative reverse-transcription PCR. RESULTS: Altogether, 117 significantly differentially expressed genes were detected at 48 h and 72 h (p < 0.05) in mitotane-treated samples relative to controls. Three significantly underexpressed genes involved in steroid hormone biosynthesis (HSD3B1, HSD3B2 and CYP21A2) and four significantly overexpressed genes (GDF15, ALDH1L2, TRIB3 and SERPINE2) have been validated. CONCLUSION: Gene-expression changes might be involved in the adrenal action of mitotane and in the inhibition of hormone secretion.
Authors: Diana Rita Szabó; Kornélia Baghy; Peter M Szabó; Adrienn Zsippai; István Marczell; Zoltán Nagy; Vivien Varga; Katalin Éder; Sára Tóth; Edit I Buzás; András Falus; Ilona Kovalszky; Attila Patócs; Károly Rácz; Peter Igaz Journal: Cell Mol Life Sci Date: 2013-06-27 Impact factor: 9.261
Authors: Vince Kornél Grolmusz; Katalin Karászi; Tamás Micsik; Eszter Angéla Tóth; Katalin Mészáros; Gellért Karvaly; Gábor Barna; Péter Márton Szabó; Kornélia Baghy; János Matkó; Ilona Kovalszky; Miklós Tóth; Károly Rácz; Péter Igaz; Attila Patócs Journal: Am J Cancer Res Date: 2016-09-01 Impact factor: 6.166
Authors: Zoltán Nagy; Kornélia Baghy; Éva Hunyadi-Gulyás; Tamás Micsik; Gábor Nyírő; Gergely Rácz; Henriett Butz; Pál Perge; Ilona Kovalszky; Katalin F Medzihradszky; Károly Rácz; Attila Patócs; Peter Igaz Journal: Am J Cancer Res Date: 2015-11-15 Impact factor: 6.166
Authors: Ewelina Stelcer; Hanna Komarowska; Karol Jopek; Agnieszka Żok; Dariusz Iżycki; Agnieszka Malińska; Beata Szczepaniak; Zhanat Komekbai; Marek Karczewski; Tomasz Wierzbicki; Wiktoria Maria Suchorska; Marek Ruchała; Marcin Ruciński Journal: Oncol Lett Date: 2022-02-10 Impact factor: 2.967
Authors: Malik Salman Haider; Taufiq Ahmad; Jürgen Groll; Oliver Scherf-Clavel; Matthias Kroiss; Robert Luxenhofer Journal: Eur J Drug Metab Pharmacokinet Date: 2021-07-21 Impact factor: 2.441